• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心肌声学造影评估冠状动脉微血管功能障碍预测射血分数保留的心力衰竭患者的主要不良心血管事件的随访。

Myocardial contrast echocardiography evaluation of coronary microvascular dysfunction to Predict MACEs in patients with heart failure with preserved ejection fraction follow-up.

机构信息

Department of Ultrasound, JinHua Municipal Central Hospital, No.365, Renmin East Road, Wucheng District, Jinhua City, 321000, Zhejiang Province, China.

Department of Cardiology, JinHua Municipal Central Hospital, Jinhua, 321000, Zhejiang, China.

出版信息

BMC Cardiovasc Disord. 2024 Sep 18;24(1):496. doi: 10.1186/s12872-024-04173-7.

DOI:10.1186/s12872-024-04173-7
PMID:39289634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11409467/
Abstract

BACKGROUND

CMD refers to the abnormalities of the tiny arteries and capillaries within the coronary artery system, which result in restricted or abnormal blood flow. CMD is an important mechanism involved in ischemic heart disease and secondary heart failure. CMD can explain left ventricular dysfunction and poor prognosis.The European Association of Cardiovascular Imaging recommends the use of MCE for the assessment of myocardial perfusion. Myocardial contrast echocardiography (MCE) is used to evaluate the accuracy of Coronary microvascular dysfunction (CMD) for predicting major adverse cardiac events (MACEs) in patients with heart failure with preserved ejection fraction (HFpEF) at follow-up.

METHODS

The clinical data of 142 patients diagnosed with HFpEF in our hospital from January 2020 to January 2022 were retrospectively summarized and stratified into 77 cases (> 1) in the CMD group and 65 cases (= 1) in the non-CMD group based on the perfusion score index (PSI) of the 17 segments of the left ventricle examined by the admission MCE, and the perfusion parameters were measured at the same time, including the peak plateau intensity (A value), the curve slope of the curve rise (βvalue) and A × β values. At a median follow-up of 27 months till October 2023, MACEs were recorded mainly including heart failure exacerbation, revascularization, cardiac death, etc. RESULTS: Increasing age, hypertension, diabetes, and coronary artery disease in the CMD group resulted in decreased left ventricular ejection fraction (LVEF), increased plasma NT-B-type natriuretic peptide (BNP) and left ventricular global longitudinal strain (LVGLS), decreased A-values and A × β-values, and an increased incidence of MACEs (P < 0.05). Univariate and multivariate Cox regression analyses showed that LVGLS (HR = 1.714, 95% CI = 1.289-2.279, P < 0.001) and A × β values (HR = 0.636, 95% CI = 0.417 to 0.969, P = 0.035) were independent predictors of MACEs in patients with HFpEF. The receiver operating characteristic curve (ROC) showed that the area under the curve (AUC) of LVGLS combined with A × β value for diagnosis of MACEs was 0.861 (95% CI = 0.761 ~ 0.961, P < 0.001), which was significantly higher than that of LVGLS or A × β value (P < 0.05). The Kaplan-Meier survival curves showed that the cumulative survival rate in CMD group was significantly lower than non-CMD group (logrank χ = 6.626, P = 0.010), with the most significant difference at 20 months of follow-up.

CONCLUSION

MCE can evaluate CMD semi-quantitatively and quantitatively, LVGLS combined with A × β value has good performance in predicting the risk of developing MACEs in patients with HFpEF at 3 years of follow-up, and CMD can be used as an important non-invasive indicator for assessing clinical prognosis.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/36b33ce55050/12872_2024_4173_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/7b0b7afc7fd2/12872_2024_4173_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/dc82df788dfc/12872_2024_4173_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/3c1bef1bcfd3/12872_2024_4173_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/36b33ce55050/12872_2024_4173_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/7b0b7afc7fd2/12872_2024_4173_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/dc82df788dfc/12872_2024_4173_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/3c1bef1bcfd3/12872_2024_4173_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6da9/11409467/36b33ce55050/12872_2024_4173_Fig5_HTML.jpg

背景

CMD 是指冠状动脉系统中小动脉和毛细血管的异常,导致血流受限或异常。CMD 是缺血性心脏病和继发性心力衰竭的重要机制。CMD 可以解释左心室功能障碍和预后不良。欧洲心血管成像协会建议使用 MCE 评估心肌灌注。心肌对比超声心动图(MCE)用于评估冠状动脉微血管功能障碍(CMD)在预测射血分数保留的心力衰竭(HFpEF)患者随访中主要不良心脏事件(MACE)的准确性。

方法

回顾性总结我院 2020 年 1 月至 2022 年 1 月期间诊断为 HFpEF 的 142 例患者的临床资料,根据入院 MCE 检查的左心室 17 节段的灌注评分指数(PSI)将患者分为 CMD 组(77 例(>1)和非 CMD 组(65 例(=1)。同时测量灌注参数,包括峰值平台强度(A 值)、曲线上升斜率(β 值)和 A×β 值。截至 2023 年 10 月,中位随访 27 个月,主要记录 MACE 事件,包括心力衰竭恶化、血运重建、心脏死亡等。

结果

CMD 组年龄较大、高血压、糖尿病和冠状动脉疾病导致左心室射血分数(LVEF)降低,血浆 NT-B 型脑钠肽(BNP)和左心室整体纵向应变(LVGLS)增加,A 值和 A×β 值降低,MACE 发生率增加(P<0.05)。单因素和多因素 Cox 回归分析显示,LVGLS(HR=1.714,95%CI=1.2892.279,P<0.001)和 A×β 值(HR=0.636,95%CI=0.417 至 0.969,P=0.035)是 HFpEF 患者 MACE 的独立预测因子。受试者工作特征曲线(ROC)显示,LVGLS 联合 A×β 值诊断 MACE 的曲线下面积(AUC)为 0.861(95%CI=0.7610.961,P<0.001),明显高于 LVGLS 或 A×β 值(P<0.05)。Kaplan-Meier 生存曲线显示,CMD 组的累积生存率明显低于非 CMD 组(logrank χ=6.626,P=0.010),在随访 20 个月时差异最显著。

结论

MCE 可以半定量和定量评估 CMD,LVGLS 联合 A×β 值在预测 HFpEF 患者 3 年随访期间发生 MACE 的风险方面具有良好的性能,CMD 可作为评估临床预后的重要无创指标。

相似文献

1
Myocardial contrast echocardiography evaluation of coronary microvascular dysfunction to Predict MACEs in patients with heart failure with preserved ejection fraction follow-up.心肌声学造影评估冠状动脉微血管功能障碍预测射血分数保留的心力衰竭患者的主要不良心血管事件的随访。
BMC Cardiovasc Disord. 2024 Sep 18;24(1):496. doi: 10.1186/s12872-024-04173-7.
2
Myocardial synchronized exercise and prognosis in patients with heart failure with preserved ejection fraction assessed by two-dimensional ultrasound speckle tracking stratified strain imaging.二维超声斑点追踪分层应变成像评估射血分数保留的心力衰竭患者的心肌同步运动与预后
Medicine (Baltimore). 2025 Jan 17;104(3):e41274. doi: 10.1097/MD.0000000000041274.
3
Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者胰岛素抵抗指数与预后的关系
Cardiovasc Diabetol. 2025 Jan 22;24(1):32. doi: 10.1186/s12933-025-02595-x.
4
The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis.射血分数保留的心力衰竭(HFpEF)中冠状动脉微血管功能障碍(CMD)的患病率:一项系统评价和荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):405-416. doi: 10.1007/s10741-023-10362-x. Epub 2023 Oct 23.
5
Correlation of serum homocysteine and cystatin C levels with prognosis in heart failure with preserved ejection fraction patients.血清同型半胱氨酸和胱抑素 C 水平与射血分数保留的心力衰竭患者预后的相关性。
BMC Cardiovasc Disord. 2024 Sep 27;24(1):510. doi: 10.1186/s12872-024-04058-9.
6
Beta-blockers in patients without heart failure after myocardial infarction.心肌梗死后无心力衰竭的患者使用β受体阻滞剂。
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565. doi: 10.1002/14651858.CD012565.pub2.
7
Evaluation of the Atherogenic Index of Plasma in the Prognostic Value of Ischemic Heart Failure Post-Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后缺血性心力衰竭预后价值中血浆致动脉粥样硬化指数的评估
Rev Cardiovasc Med. 2025 Jun 30;26(6):33470. doi: 10.31083/RCM33470. eCollection 2025 Jun.
8
AI-Defined Cardiac Anatomy Improves Risk Stratification of Hybrid Perfusion Imaging.人工智能定义的心脏解剖结构提高了杂交灌注成像的风险分层。
JACC Cardiovasc Imaging. 2024 Jul;17(7):780-791. doi: 10.1016/j.jcmg.2024.01.006. Epub 2024 Mar 6.
9
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
10
Sex-specific cardiometabolic multimorbidity, metabolic syndrome and left ventricular function in heart failure with preserved ejection fraction in the UK Biobank.英国生物银行中射血分数保留的心力衰竭患者的性别特异性心脏代谢多重疾病、代谢综合征与左心室功能
Cardiovasc Diabetol. 2025 Jun 4;24(1):238. doi: 10.1186/s12933-025-02788-4.

引用本文的文献

1
Value of high-density lipoprotein cholesterol, myocardial perfusion index, and global longitudinal strain derived from cardiac magnetic resonance imaging in predicting coronary slow flow in patients with nonobstructive coronary artery disease.心脏磁共振成像得出的高密度脂蛋白胆固醇、心肌灌注指数和整体纵向应变在预测非阻塞性冠状动脉疾病患者冠状动脉慢血流中的价值。
Quant Imaging Med Surg. 2025 Sep 1;15(9):8491-8504. doi: 10.21037/qims-24-1668. Epub 2025 Aug 11.
2
Coronary microvascular disease in heart failure with preserved ejection fraction.射血分数保留的心力衰竭中的冠状动脉微血管疾病
Physiol Rep. 2025 Aug;13(16):e70521. doi: 10.14814/phy2.70521.
3

本文引用的文献

1
The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis.射血分数保留的心力衰竭(HFpEF)中冠状动脉微血管功能障碍(CMD)的患病率:一项系统评价和荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):405-416. doi: 10.1007/s10741-023-10362-x. Epub 2023 Oct 23.
2
Invasive Detection of Coronary Microvascular Dysfunction: How It Began, and Where We Are Now.冠状动脉微血管功能障碍的侵入性检测:它是如何开始的,以及我们现在所处的位置。
Interv Cardiol. 2023 Mar 7;18:e07. doi: 10.15420/icr.2022.30. eCollection 2023.
3
Molecular mechanisms of endothelial dysfunction in coronary microcirculation dysfunction.
Predictive value of NLR, PLR and MPVLR for recent major cardiovascular adverse events in elderly patients with heart failure.
中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及平均血小板体积与淋巴细胞比值对老年心力衰竭患者近期主要心血管不良事件的预测价值
Am J Transl Res. 2025 Jul 15;17(7):4964-4975. doi: 10.62347/XQNT2355. eCollection 2025.
4
Association between segmental noninvasive longitudinal strain and quantitative microvascular perfusion in ST-segment elevation myocardial infarction: implications for clinical outcomes.ST段抬高型心肌梗死节段性无创纵向应变与定量微血管灌注之间的关联:对临床结局的影响
BMC Cardiovasc Disord. 2025 Feb 18;25(1):109. doi: 10.1186/s12872-025-04547-5.
冠状动脉微循环功能障碍中内皮功能障碍的分子机制。
J Thromb Thrombolysis. 2023 Oct;56(3):388-397. doi: 10.1007/s11239-023-02862-2. Epub 2023 Jul 19.
4
Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies.冠状动脉微血管功能障碍与心血管疾病:发病机制、相关性及治疗策略。
Biomed Pharmacother. 2023 Aug;164:115011. doi: 10.1016/j.biopha.2023.115011. Epub 2023 Jun 13.
5
Early diagnosis of coronary microvascular dysfunction by myocardial contrast stress echocardiography.心肌声学造影超声心动图早期诊断冠状动脉微血管功能障碍。
Math Biosci Eng. 2023 Feb 21;20(5):7845-7858. doi: 10.3934/mbe.2023339.
6
Coronary microvascular dysfunction: A review of recent progress and clinical implications.冠状动脉微血管功能障碍:近期进展与临床意义综述
Front Cardiovasc Med. 2023 Jan 26;10:1111721. doi: 10.3389/fcvm.2023.1111721. eCollection 2023.
7
Coronary microcirculation dysfunction evaluated by myocardial contrast echocardiography predicts poor prognosis in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention.心肌声学造影评估冠状动脉微循环功能障碍对经皮冠状动脉介入治疗后 ST 段抬高型心肌梗死患者预后的预测价值。
BMC Cardiovasc Disord. 2022 Dec 28;22(1):572. doi: 10.1186/s12872-022-02947-5.
8
Global trends and frontiers in research on coronary microvascular dysfunction: a bibliometric analysis from 2002 to 2022.全球冠状动脉微血管功能障碍研究的趋势和前沿:2002 年至 2022 年的文献计量分析。
Eur J Med Res. 2022 Nov 5;27(1):233. doi: 10.1186/s40001-022-00869-8.
9
Assessment and Treatment for Coronary Microvascular Dysfunction by Contrast Enhanced Ultrasound.经造影增强超声评估与治疗冠状动脉微血管功能障碍
Front Cardiovasc Med. 2022 Jun 20;9:899099. doi: 10.3389/fcvm.2022.899099. eCollection 2022.
10
Definition and epidemiology of coronary microvascular disease.冠状动脉微血管疾病的定义和流行病学。
J Nucl Cardiol. 2022 Aug;29(4):1763-1775. doi: 10.1007/s12350-022-02974-x. Epub 2022 May 9.